Introduction
Cellular immunotherapy for malignancies targeting various tumor-associated antigens has been developed. 1, 2 Recently, some attractive target antigens recognized by leukemia-reactive cytotoxic T lymphocytes (CTLs), such as WT1 and PR1, have been discovered and phase I/II clinical studies of cancer immunotherapy targeting these antigens have been conducted; however, the clinical response against hematological malignancies still remains unsatisfactory. 3, 4 To establish effective cancer immunotherapy, identification of target antigens that are recognized efficiently by tumor-specific CTLs is necessary. Antigens that can serve as ideal targets recognizable by tumor-specific CTLs need to have several essential characteristics. First, their expression should be limited to, or abundant in, tumor cells rather than normal cells.
Second, the antigens should be efficiently processed in tumor cells and expressed on the cell surface in context with common HLA molecules. Third, target antigens should play an important role in tumorigenesis and/or progression of malignancies, because their expression is essential for tumor survival.
Aurora-A kinase (Aur-A) is a member of the serine/threonine kinase family, and the Aur-A gene is located at chromosome 20q13, a region frequently amplified in breast cancer. 5 Aur-A is mainly expressed in the G2/M phase of the cell cycle and regulates mitotic cell division in normal cells. [6] [7] [8] Among normal tissues, Aur-A is expressed exclusively in testis, but in various kinds of cancer it is aberrantly overexpressed, and associated with poor prognosis. [9] [10] [11] [12] [13] [14] Overexpression of Aur-A determined by amplification of Aur-A mRNA has also been widely observed in hematological malignancies. [15] [16] [17] [18] [19] Aur-A overexpression has been linked with centrosome amplification, aneuploidy, and chromosome instability. 20, 21 Furthermore, ectopic overexpression of For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Aur-A efficiently transforms immortalized rodent fibroblasts. 9, 20 These data strongly suggest that Aur-A is one of the fundamental cancer-associated genes and a potential target for cancer treatment. In addition, previous reports have demonstrated that silencing of the gene encoding Aur-A in cancer cells results in inhibition of their growth and enhancement of the cytotoxic effect of anti-cancer agents. 22 Therefore the development of small molecules with an Aur-A-inhibitory function may make it possible to reduce or block the oncogenic activity of Aur-A. On the basis of this concept, clinical studies using Aur-A inhibitors for cancer treatment are now underway; however, their clinical efficacy is still unknown. [23] [24] [25] [26] [27] The biological characteristics of Aur-A mentioned above suggest that it is an ideal target for tumor-specific CTLs, and that cancer immunotherapy targeting Aur-A could be feasible. In this study, therefore, we attempted to verify the feasibility of cellular immunotherapy for leukemia targeting
Aur-A.
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Methods

Synthetic peptides
Candidate peptides derived from Aur-A with high binding affinity for the HLA-A*0201 or HLA-A*2402 molecule were predicted algorithmically by the BIMAS program (http://www-bimas.cit.nih.gov/molbio/hla_bind/). On the basis of these data, peptides with favorable binding affinity for the HLA-A*0201 or HLA-A*2402 molecule were selected and synthesized (Thermo Electron GmbH; Greiner Bio-One Co. Ltd., Tokyo, Japan). Amino acid sequences of the peptides used in this study are listed in Table 1 . All the peptides were synthesized with a purity exceeding 80%.
HLA peptide-binding assay
Binding affinity of peptides for the HLA-A*0201 or HLA-A*2402 molecule was assessed by an HLA-A*0201 or HLA-A*2402 stabilization assay as described previously. 28, 29 Briefly, HLA-A*0201-positive cell line (T2) or HLA-A*2402 gene-transfected T2 cell line (T2-A24) was plated in 24-well plates at 1×10 6 cells per well and incubated overnight with the candidate peptides at a concentration of 10 μmol/L in serum-free RPMI1640 medium. The T2 and T2-A24 cells were washed twice with phosphate-buffered saline (PBS), and then incubated with fluorescein isothiocyanate (FITC)-conjugated anti-HLA-A2 or HLA-A24 monoclonal antibody (MoAb) (One Lambda, Canoga Park, CA) at 4C° for 20 min. The cells were washed and suspended in 1 mL of PBS and analyzed using a flow cytometer (FACSCalibur;
Becton Dickinson, San Jose, CA). Measurement of mean fluorescence intensity and analysis of data were done with Cell Quest Software (Becton Dickinson). The fluorescence index (FI) was calculated as FI = (sample mean -background mean) / 
Cell lines, freshly isolated leukemia cells, and normal cells
Approval for this study was obtained from the institutional review board of Ehime from healthy donors were isolated and stored in liquid nitrogen until use. All leukemia samples contained more than 95% leukemia cells. CD34 + cells from BMMCs and CBMCs were isolated using CD34 + cell-isolating immunomagnetic beads (MACS beads; Miltenyi Biotec, Auburn, CA). In some experiments, BMMCs and CBMCs were stained with FITC-conjugated anti-CD34 MoAb and phycoerythrin (PE)-conjugated anti-CD38 MoAb, and CD34 + CD38 high cells and CD34 + CD38 low cells were sorted with an EPICS ALTRA cell sorter (Beckman-Coulter, Fullerton, CA).
Generation of Aur-A peptide-specific CTL lines
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Aur-A peptide-specific CTLs were generated as described previously. 30 The Aur-A peptide-specific cytotoxic activity of growing cells was examined by standard 51 Cr-release assay.
Cytotoxicity assays
The standard 51 Cr-release assays were performed as described previously. 31 Briefly, 
Quantitative analysis of Aur-A mRNA expression
Total RNA was extracted from each sample with an RNeasy Mini kit (Qiagen GmbH, Hilden, Germany) in accordance with the manufacturer's instructions. Quantitative level of Aur-A mRNA was corrected by reference to that of GAPDH mRNA, and the relative amount of Aur-A mRNA in each sample was calculated by the comparative ΔCt method.
Western blotting of Aur-A protein
Western blotting was performed as follows. Briefly, 1×10 6 cells were lysed in lysis buffer (25 mM HEPES, pH 7.5, 1% NP-40, 50 mM NaCl, 5 mM EDTA) with a protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland), and then incubated on ice, sonicated, frozen, and thawed. After centrifugation at 12,000×g for 15 min at 4C°, the supernatant was collected as the lysate. After addition of sodium dodecyl sulfate (SDS) buffer, the total cell lysates were subjected to 10% SDS-polyacrylamide gel electrophoresis (PAGE), and blotted onto nitrocellulose membranes. The blots were reacted with anti-Aur-A mouse MoAb (Abcam, Cambridge, UK) followed by incubation with horseradish peroxidase-conjugated anti-mouse IgG antibody (GE Healthcare UK Ltd., Buckinghamshire, UK). The probed proteins were visualized using an enhanced chemiluminescence system (GE Healthcare UK Ltd.). The blotted membranes were also examined with anti-β-actin mouse MoAb (Sigma-Aldrich, St.
Louis, MO) to confirm that samples of equal volume had been loaded.
Detection of Aur-A 207-215 -specific CTL precursors in leukemia patients and healthy individuals by tetramer assays and enzyme-linked immunospot (ELISPOT) assays
HLA-A*0201/Aur-A 207-215 peptide and HLA-A*2402/Aur-A 207-215 peptide tetramers were produced as described previously. 32, 33 Briefly, recombinant HLA-A*0201 or HLA-A*2402 and the β 2 -microglobulin molecule were generated by the gene-transfer ELISPOT assays were carried out as described previously. 33 Briefly, 96-well flat-bottomed MultiScreen-HA plates with a nitrocellulose base (Millipore, Bedford, MA) were coated with 10 μg/mL anti-interferon (IFN)-γ MoAb (R&D Systems) and incubated overnight at 4C°. After being washed with PBS, the plates were blocked with the assay medium for 1 hour at 37C°. T2-A24 cells (5.0×10 4 /well) were pulsed with Aur-A 207-215 peptide at a concentration of 10 μmol/L or with PBS alone, and incubated in RPMI 1640 medium supplemented with 10% FCS for 1 hour at 37C°. Then, the 1 1 responder cells generated as above were seeded into each well to mix with the target peptide-loaded T2-A24 cells, and the plates were incubated in a 5% CO 2 incubator at 37°C for 20 hours. After incubation, plates were washed vigorously with PBS containing 0.1% Tween 20. A polyclonal rabbit anti-IFN-γ antibody (Endgen, Woburn, MA) was added to each well and the plates was left for 90 min at room temperature, followed by exposure to peroxidase-conjugated goat anti-rabbit IgG (Zymed, San 
Results
Binding activities of Aur-A peptides for HLA-A*0201 and A*2402 molecules
The BIMAS-predicted binding scores and results of the binding assay for the HLA-A*0201 and A*2402 molecules with the three candidate Aur-A peptides and the positive and negative control peptides are summarized in Table 1 . Among the three candidate Aur-A peptides, Aur-A 207-215 showed high binding affinity for HLA-A*0201 in comparison with the others. Interestingly, Aur-A 207-215 peptide appeared to be capable of binding to HLA-A*2402 as well as HLA-A*0201. These data suggest that Aur-A 207-215 peptide can elicit Aur-A-specific CTLs. Figure 2B ). As shown in Figure 2C , cytotoxicity against leukemia cell lines mediated by AUR-1 was inhibited by addition of anti-HLA class I framework MoAb but not anti-HLA-DR MoAb. The cold target inhibition assay showed that the cytotoxicity of AUR-1 against the HLA-A*0201-positive leukemia cell line was 1 4 significantly abrogated by adding 51 Cr-unlabeled Aur-A 207-215 peptide-loaded autologous LCL, but not HLA-A*0201-negative allogeneic LCL, indicating that the cytotoxicity of AUR-1 against leukemia cells is Aur-A-specific ( Figure 2D) . These results show that AUR-1 can exert cytotoxicity against leukemia cell lines in an HLA-A*0201-restricted manner through recognition of the Aur-A 207-215 epitope that is naturally processed from Aur-A protein in leukemia cells and presented on the cell surface in the context of HLA class I molecules.
Establishment of an Aur-A 207-215 peptide-specific CTL line
Freshly isolated leukemia cells, but not normal PBMCs or normal mitotic cells, express Aur-A abundantly and are lysed by AUR-1
Next, we examined whether Aur-A-specific CTLs can discriminate freshly isolated leukemia cells from normal cells and whether AUR-1 can lyse freshly isolated leukemia cells as well as leukemia cell lines. As shown in Figure 3A HLA-A*0201-positive normal PBMCs, and HLA-A*0201-positive PHA lymphoblasts were resistant to AUR-1-mediated cytotoxicity ( Figure 3B ). Taken together, Aur-A-specific CTLs appeared to be capable of discriminating leukemia cells from normal cells in an HLA-restricted manner.
CD34 + leukemia progenitor cells, but not CD34 + normal hematopoietic progenitor cells, express Aur-A abundantly and are susceptible to AUR-1-mediated cytotoxicity
Because it is important to determine whether Aur-A-specific CTLs can specifically recognize and lyse leukemia progenitors, we further examined Aur-A expression and susceptibility to AUR-1-mediated cytotoxicity of CD34 + fractions in leukemia cells and normal hematopoietic cells. The CD34 + cells were sorted from BMMCs of patients with CML and CBMCs, and their Aur-A mRNA expression was examined by QRT-PCR. As shown in Figure 4A , the expression levels of Aur-A mRNA in CML CD34 + progenitor cells appeared to be significantly higher than in normal CD34 + hematopoietic progenitor cells. Because it is suggested that leukemia stem cells and normal hematopoietic stem cells are present in the CD34 + CD38 low fraction, we further examined Aur-A expression in CD34 + CD38 low cells of CML BMMCs and CBMCs. Consequently, it appeared that Aur-A mRNA was abundantly expressed in the CD34 + CD38 low fraction of CML ( Figure   4B ); however, the expression level of Aur-A mRNA in the CD34 + CD38 low fraction of normal hematopoietic progenitors was significantly low ( Figure 4C ).
Since a sufficient number of CD34 + CD38 low cells could not be obtained, whole CD34 + cells were used as target cells for cytotoxicity assays ( Figure 4D ). As expected, two patients. In contrast, AUR-1 did not show any cytotoxicity against normal CD34 + hematopoietic progenitor cells. These data strongly suggest that Aur-A-specific CTLs can discriminate leukemia progenitor cells from normal hematopoietic stem cells and selectively inhibit the growth of leukemia stem cells, and that immunotherapy targeting Aur-A is effective and safe.
AUR-1 exerted strong cytotoxicity against CD34 + cells isolated from CML BMMCs of
Presence of Aur-A 207-215 -specific CTL precursors in peripheral blood of leukemia patients
When considering the feasibility of cellular immunotherapy for leukemia targeting in Figure 5B . Consequently, Aur-A 207-215 -specific CTL precursors were apparently detected in both HLA-A*0201-positive and HLA-A*2402-positive patients with leukemia. The frequency of Aur-A 207-215 -specific CTL precursors in leukemia patients appeared to be significantly higher than that in healthy individuals (0.25 ± 0.1% for leukemia patients, and 0.05 ± 0.03% for healthy individuals, P<0.001). These data strongly suggest that Aur-A-specific CTL precursors are primed in patients with leukemia, and that vaccination with Aur-A peptide may efficiently induce an
Aur-A-specific immune response in leukemia patients. To determine whether
Aur-A 207-215 -specific CTL precursors detected by tetramer assays are indeed functional, we performed tetramer assays and ELISPOT assays using the same samples simultaneously, and determined the correlation between the two sets of data. PBMCs isolated from seven HLA-A*0201-or HLA-A*2402-positive individuals were used for tetramer assays and ELISPOT assays. Consequently, the frequencies of peptide-specific CTL precursors detected by these two different assay systems appeared to be closely correlated (r=0.817) (Supplemental data 1B). These data strongly suggest that Aur-A tetramer-positive cells certainly have a functional response to stimulation with Aur-A.
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Discussion
In the present study, we demonstrated that Aur-A is an ideal target antigen of cellular immunotherapy for leukemia, based on the following findings. First, Aur-A is broadly overexpressed in various types of leukemia but not in normal tissues except for testis, which is negative for HLA expression. Second, an Aur-A-derived peptide, Aur-A 207-215 , can bind to HLA-A*0201 and HLA*2402 molecules and elicit Aur-A-specific CTLs.
Third, Aur-A is efficiently processed in leukemia cells, and leukemia cell lines and freshly isolated leukemia cells, but not normal cells, are lysed by Aur-A-specific CTLs in an HLA class I-restricted manner. Fourth, Aur-A-specific CTL precursors are certainly present in the peripheral blood of patients with leukemia.
One of the important characteristics of proteins that could be used as ideal tumor-associated antigens for cancer immunotherapy is an essential role in tumorigenesis and/or tumor progression. Aur-A is localized mainly at spindle poles and the mitotic spindle during mitosis, where it regulates the functions of centrosomes, spindles, and kinetochores required for proper mitotic progression. Recent studies have revealed that Aur-A is frequently overexpressed in various cancer cells, indicating its involvement in tumorigenesis. [9] [10] [11] [12] [13] [14] Overexpression of Aur-A contributes to genetic instability and tumorigenesis by disrupting the proper assembly of the mitotic checkpoint complex at the level of the Cdc20-BubR1 interaction. 34 Its overexpression also causes resistance to apoptosis induced by taxol in human cancer cell lines. 35, 36 Moreover, Aur-A is a key regulatory component of the p53 pathway, as its overexpression leads to increased p53 degradation, thus facilitating oncogenic transformation. 37 In addition, Aur-A expression in tumors is often associated with poor histologic differentiation and poor prognosis. [12] [13] [14] These characteristics indicate that 1 9 Aur-A is an ideal target antigen for cancer immunotherapy. Although Aur-A is also expressed in normal cells during mitosis, its expression level in normal tissue is quite low; therefore, normal mitotic cells are resistant to Aur-A-specific CTL-mediated cytotoxicity, as shown in the present study.
As reported previously, [17] [18] [19] the present study demonstrated that Aur-A is overexpressed widely in various types of leukemia including AML, ALL, and CML.
Among the leukemias, CML cells appeared to express a large amount of Aur-A. It was also found that Aur-A is abundantly expressed in the CD34 + CD38 low fraction of CML cells. Previous gene expression profiling analysis has also shown that mitogen-activated protein kinases, which activate mitotic kinases including Aurora kinases, are overexpressed in CD34 + progenitor cells in CML. 38 In contrast to overexpression of Aur-A in the CD34 + CD38 low fraction of CML cells, the expression level of Aur-A in the CD34 + CD38 low fraction of normal hematopoietic progenitors appeared to be markedly lower than that in leukemic cells. We therefore addressed the question of whether Aur-A-specific CTLs can lyse leukemic progenitors. Because a sufficient number of CD34 + CD38 low cells could not be obtained, CD34 + cells were used as target cells.
Consequently, in parallel with the expression levels of Aur-A, CD34 + CML cells but not CD34 + normal hematopoietic progenitor cells were efficiently lysed by Aur-A-specific CTLs. Although the detailed characteristics of leukemic stem cells are still obscure, they are considered to be present in the CD34 + CD38 low fraction. [39] [40] [41] Taken together, targeting of Aur-A may be effective for eradicating leukemic stem cells.
Another interesting finding of this study was that Aur-A 207-215 peptide is able to bind to HLA-A*2402 as well as to HLA-A*0201. Although AUR-1 could not recognize the complex of Aur-A 207-215 peptide and HLA-A*0206 or HLA-A*0207, this peptide can In summary, we have demonstrated for the first time that Aur-A is a potentially ideal 
Figure 5. Detection of Aur-A 207-215 -specific CTL precursors in patients with
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